In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors.
Jianhao ZengDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1026-729X Tyler Ellis PappDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-5116-0782 Awurama AkyianuDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0005-2287-3843 Alejandra BahenaDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0005-1311-2188 Lanfranco LeoDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-3000-6097 Faris HalilovicDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0002-3052-6831 Hamideh ParhizDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-2880-2836 Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6MTRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GARY D. WU · 1997 to 2026
$32.5MEliminating the latent reservoir by targeted in vivo delivery of HIV-specific CARsR01AI167061 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Hamideh Parhiz, James L. Riley · 2023 to 2026
$2.9MPredoctoral Training Grant in PharmacologyT32GM154643 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Julie A Blendy · 2025 to 2026
$1.1MNCI NIH HHS P30 CA016520NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI167061NIDDK NIH HHS P30 DK050306NIGMS NIH HHS T32 GM154643
6 · The paper itselfAbstract
Targeted lipid nanoparticles (tLNPs) enable efficient mRNA delivery to T cells, allowing for
Indexed as
CD7in vivo CAR-TmRNA deliveryReceptor internalizationTargeted lipid nanoparticles (tLNPs)T cells
Identifiers
PMID41659486
PMCPMC12874055
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390